TASK DEFINITION: In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.
PROBLEM: The renin-angiotensin system plays an important role in the maintenance of blood pressure homeostasis. The angiotensin-converting enzyme (ACE) converts angiotensin I into angiotensin II. Angiotensin II, which binds the angiotensin II type-1 receptor (AT1R), is a potent vasoconstrictor. On a pathophysiological basis, both ACE I/D and AT1R A1166C polymorphism lead to an enhanced activity of the angiotensin II-AT1R axis, thereby possibly contributing to circulatory disturbances. A mutually facilitatory effect may be presumed between the two polymorphisms. We examined whether this synergistic effect is involved in the evolution of different types of ischemic stroke. Genetic and clinical data on 308 consecutive patients with acutely developing ischemic stroke were analyzed. A total of 272 stroke and neuroimaging alteration-free subjects served as a control group. Univariate and logistic regression statistical approaches were used. The ACE D allele combined with the AT1R 1166C allele did not yield a risk of ischemic stroke. However, the co-occurrence of the homozygous ACE D/D and at least one AT1R 1166C allele was more frequent in the ischemic stroke group than in the control group (22.4 vs 11%, p < 0.005, OR, 2.33; 95% CI, 1.46-3.7). After specific subgroup analysis, this synergistic association was even stronger for small-vessel ischemic stroke (OR, 3.44; 95% CI, 1.9-6.24; p < 0.0005). Multivariate logistic regression analysis of the data confirmed this association (adjusted OR, 3.54, 95% CI, 1.88-7.16; p < 0.0005). Our results demonstrate that ACE D/D and AT1R 1166C NeuroMolecular Medicine

SOLUTION: Coexistence of Angiotensin II Type-1 Receptor A1166C and Angiotensin-Converting Enzyme D/D Polymorphism Suggests Susceptibility for Small-Vessel-Associated Ischemic Stroke

PROBLEM: Streptococcus pneumoniae is the main cause of diseases such as meningitis, pneumoniae and sepsis, especially in children and old people. Due to costly antibiotic treatment, and increasing resistance of pneumococcus, developing high-efficient protective vaccine against this pathogen is an urgent need. Although the pneumoniae polysaccharide vaccine (PPV) and pneumonia conjugate vaccines (PCV) are the efficient pneumococcal vaccine in children and adult groups, but the serotype replacement of S. pneumoniae strains causes the reduction in efficacy of such vaccines. For overcoming the aforesaid drawbacks epitope-based vaccines are introduced as the relevant alternative. In our previous research, the epitope vaccine was designed based on immunodominant epitopes from PspA, CbpA antigens as cellular stimulants and PhtD, PiuA as humoral stimulants. Because the low immunogenicity is the main disadvantage of epitope vaccine, in the current study, we applied coiled-coil selfassembled structures for developing our vaccine. Recently, self-assembled peptide nanoparticles (SAPNs) have gained much attention in the field of vaccine development due to their multivalency, self-adjuvanticity, biocompatibility, and size similarity to pathogen. In this regard, the final designed vaccine is comprised of cytotoxic T lymphocytes (CTL) epitopes from PspA and CbpA, helper T lymphocytes (HTL) epitopes from PhtD and PiuA, the pentamer and trimmer oligomeric domains form 5-stranded and 3-stranded coiled-coils as self-assembled scaffold, Diphtheria toxoids (DTD) as a universal T-helper, which fused to each other with appropriate linkers. The four different arrangements based on the order of above-mentioned compartments were constructed, and each of them were modeled, and validated to find the 3D structure. The structural, physicochemical, and immunoinformatics analyses of final vaccine construct represented that our vaccine could stimulate potent immune response against S. pneumoniae; however, the potency of that should be approved via various in vivo and in vitro immunological tests.

SOLUTION: Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy

PROBLEM: The Middle East respiratory syndrome (MERS) is a new human disease caused by a novel coronavirus (CoV). The disease is reported mainly in adults. Data in children are scarce. The disease caused by MERS-CoV in children presents with a wide range of clinical manifestations, and it is associated with a lower mortality rate compared with adults. Poor outcome is observed mainly in admitted patients with medical comorbidities. We report a new case of MERS-CoV infection in a 9-month-old child complicated by severe respiratory symptoms, multi-organ dysfunction, and death. We reviewed the literature in an attempt to characterize the mode of presentation, the risk factors, and outcome of MERS-CoV infection in the pediatric population.

SOLUTION:
Middle East respiratory syndrome coronavirus in children ‫اجلديدة‬ ‫البشرية‬ ‫األمراض‬ ‫من‬ ‫التنفسية‬ ‫األوسط‬ ‫الشرق‬ ‫متالزمة‬ ‫تعد‬ ‫الفيروس‬ ‫هذا‬ ‫انتشر‬ ‫ولقد‬ ‫اجلديد.‬ ‫كورونا‬ ‫فيروس‬ ‫بها‬ ‫تسبب‬ ‫التي‬ ‫املعلومات‬ ‫كانت‬ ‫حني‬ ‫في‬ ‫املنشورة،‬ ‫التقارير‬ ‫حسب‬ ‫البالغني‬ ‫بني‬ ً ‫غالبا‬ ‫فيروس‬ ‫يظهر‬ ‫اآلن.‬ ‫حتى‬ ‫نادرة‬ ‫األطفال‬ ‫بني‬ ‫الفيروس‬ ‫هذا‬ ‫عن‬ ‫املنشورة‬ ‫أنه‬ ‫كما‬ ‫السريرية،‬ ‫املظاهر‬ ‫من‬ ‫كبيرة‬ ‫مبجموعة‬ ‫األطفال‬ ‫بني‬ ‫كورونا‬ ‫البالغني.‬ ‫بني‬ ‫عنها‬ ‫اإلبالغ‬ ‫مت‬ ‫التي‬ ‫تلك‬ ‫من‬ ‫أقل‬ ‫وفيات‬ ‫مبعدل‬ ‫مرتبط‬ ‫من‬ ‫يعانون‬ ‫الذين‬ ‫املرضى‬ ‫بني‬ ‫السيئة‬ ‫املرض‬ ‫نتائج‬ ‫ُالحظ‬ ‫ت‬ ‫ما‬ ً ‫وغالبا‬ ‫من‬ ‫يبلغ‬ ‫طفل‬ ‫حالة‬ ‫املقال‬ ‫هذا‬ ‫في‬ ‫نستعرض‬ ‫أخرى.‬ ‫صحية‬ ‫مشاكل‬ ‫أعراض‬ ‫إلى‬ ‫باإلضافة‬ ‫كورونا،‬ ‫بفيروس‬ ‫صيب‬ ُ ‫أ‬ ‫وقد‬ ‫أشهر،‬ 9 ‫العمر‬ ‫بالبحث‬ ‫قمنا‬ ‫لقد‬ ‫املوت.‬ ‫ثم‬ ‫ومن‬ ‫متعدد‬ ‫عضوي‬ ‫وفشل‬ ‫حادة‬ ‫تنفسية‬ ‫التي‬ ‫السريرية‬ ‫املظاهر‬ ‫وصف‬ ‫محاولة‬ ‫في‬ ‫وذلك‬ ‫العلمي‬ ‫األدب‬ ‫في‬ ‫بهذا‬ ‫اإلصابة‬ ‫خطر‬ ‫من‬ ‫تزيد‬ ‫التي‬ ‫والعوامل‬ ‫املرضى،‬ ‫هؤالء‬ ‫بها‬ ‫يظهر‬ ‫األطفال.‬ ‫بني‬ ‫املرض‬ ‫هذا‬ ‫ملثل‬ ‫املتوقعة‬ ‫النتائج‬ ‫وكذلك‬ ‫الفيروس،‬ Case Report